# Arda Therapeutics

> Arda Therapeutics is a San Carlos, California biotech building precision biologics that eliminate the specific cells driving chronic disease rather than tinkering with the proteins those cells produce. Using a single-cell data discovery engine, Arda maps disease-specific cell states, pinpoints their surface markers, and designs targeted therapies that deplete only the harmful cells while sparing healthy tissue. Founded in 2021 by former Calico scientist Adam Freund, the company is applying lessons from oncology to fibrosis, autoimmune, and metabolic disease, backed by a $43M Series A led by a16z Bio + Health.

- **Founded:** 2021
- **Headquarters:** San Carlos, California, United States
- **Founders:** Adam Freund (Founder & CEO), Rémi Laberge (Co-founder & CTO)
- **Team size:** ~21 employees
- **Products:** Single-cell discovery engine, Targeted cell depletion biologics
- **Notable:** Closed a $43M Series A in October 2024 led by a16z Bio + Health., Raised roughly $50.5M total to date., Recruited Scott Turner, Ph.D. (ex-Pliant Therapeutics CSO) as Chief Scientific Officer.

## Products & services

- **Single-cell discovery engine** — A computational platform that integrates single-cell sequencing data from patient tissue to catalog cell states, identify pathogenic cell subpopulations, and surface the cell-surface markers that distinguish them.
- **Targeted cell depletion biologics** — Precision biologics designed to bind disease-specific surface markers and selectively eliminate pathogenic cells, leaving healthy tissue intact - an approach borrowed from oncology (chemotherapy, CAR-T) and applied to non-cancer chronic disease.

## Achievements

- Closed a $43M Series A in October 2024 led by a16z Bio + Health.
- Raised roughly $50.5M total to date.
- Recruited Scott Turner, Ph.D. (ex-Pliant Therapeutics CSO) as Chief Scientific Officer.
- Built a single-cell discovery engine to map disease-specific cell states and surface markers.

## Latest updates

- **2024-10** — Announced $43M Series A financing led by a16z Bio + Health to advance targeted cell depletion therapies.
- **2024-10** — Appointed Scott Turner, Ph.D., formerly CSO of Pliant Therapeutics, as Chief Scientific Officer.

## Links

- Website: https://ardatx.com
- LinkedIn: http://www.linkedin.com/company/arda-therapeutics
- Twitter/X: https://twitter.com/arda_tx

---

Profile page: https://yespress.io/arda-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-16